In order to prevent spam,
this email address cannot be copied.
Researcher Profile - Ralf Ihl Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Community: Researcher Profiles
Researcher Profile

RESEARCHER INFORMATION
First Name:Ralf
Last Name:Ihl
Title:Prof. Dr.
Affiliation:Alexian Hospital
Department:Geriatric Psychiatry
Street Address 1:Diessemer Bruch 81
City:Krefeld
State/Province:NRW
Zip/Postal Code:D-47805
Country/Territory:Germany
Phone:21513347904
Fax:21513347901
Email Address: 
Disclosure:
(view policy) 
Member reports the following financial or other potential conflicts of interest: [Last Modified: 1 November 2012]

2010-2012

Funding
Research support:Bundesministerium für Gesundheit; Aktion Psychisch Kranke e.v.; European Union
Employment
Alexian Hospital, Krefeld; Consulting and Advisory boards honoraria: APK, Amtsgericht Krefeld, Landgericht Düsseldorf, Landgericht Wuppertal, Landgericht Duisburg. Speakers honoraria: Global Life Sciences, GE Healthcare, IFE, BDI, Double Helix Development, Merz, Bezirksregierung Arnsberg, Austroplant, Caritas Siegen, KDA, Lebenswerk, LVR Düren, Medical Tribune, Pierrel, Pfrimmer Nutritia GmbH, Schwabe. Royalties:
Beltz Test, BOD, Friedrichverlag, Hogrefe, Med. Komm., Thieme, Urban & Vogel, Westermayer
Personal financial interests: None
View all comments by Ralf Ihl
Clinical Interests:
Aging Process, Alzheimer Disease
Research Focus:
Clinical trials, Diagnosis
Work Sector(s):
Medical hospital
Web Sites:
Professional: www.alexianer.de
Researcher Bio
Academic Background

Year Degree Place
1983 Diploma in Psychology U Mainz
1985 Licensure U Mainz
1986 Medical doctor U Wuerzburg
1991 Doctor of Neuropsychiatry Bayerische Landesärztekammer
1997 Priv.-Doc. U Duesseldorf
2002 Professor of PsychiatryU Duesseldorf

Professional Experience

1983 – 1993 Department of Psychiatry, University of Wuerzburg, Psychiatrist
1993 - 2005 Department of Psychiatry, University of Duesseldorf, Head of the Laboratory of Neurophysiology and Psychophysiology
Vice-chair of the Department of Geriatric Psychiatry
2005 – present Alexian Hospital Cologne, head of department
2007 - present Alexian Hospital Krefeld, head of department

Professional Society Memberships

Board Memberships

Since 1988 International Society for Neuroimaging in Psychiatry Board of directors (Secretary and founding member)
10/1992-11/1997 German Alzheimer Association
Vice-president and founding member
Since 1998 German Brain League Board of directors (Secretary)
2004-2011 European Association of Geriatric Psychiatry President
Top Papers
Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller HJ; WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias. World Federation of Societies of Biological Psychiatry (WFSBP)guidelines for the biological treatment of Alzheimer's disease and other dementias.
World J Biol Psychiatry. 2011 Feb;12(1):2-32.
PMID: 21288069
Katona C, Chiu E, Adelman S, Baloyannis S, Camus V, Firmino H, Gove D, Graham N, Ghebrehiwet T, Icelli I, Ihl R, Kalasic A, Leszek L, Kim S, Lima Cde M, Peisah C, Tataru N, Warner J. World psychiatric association section of old age psychiatry consensus statement on ethics and capacity in older people with mental disorders. Int J Geriatr Psychiatry. 2009 Dec;24(12):1319-24.
PMID: 19472302
Ihl R, Ferris S, Robert P, Winblad B, Gauthier S, Tennigkeit F. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Int J Geriatr Psychiatry. 2012 Jan;27(1):15-21. doi: 10.1002/gps.2679. Epub 2011 Mar 8.
PMID: 21384431Ihl R, Frölich L, Dierks T, Martin EM, Maurer K. Differential validity of psychometric tests in dementia of the Alzheimer type. Psychiatry Res. 1992 Nov;44(2):93-106. PMID: 1480682
Ihl R, Dierks T, Martin EM, Frölich L, Maurer K.Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type. Biol Psychiatry. 1996 Mar 1;39(5):319-25.
PMID: 8704062
Prior R, D'Urso D, Frank R, Prikulis I, Cleven S, Ihl R, Pavlakovic G.Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques. Am J Pathol. 1996 Jun;148(6):1749-56. PMID: 8669461
Ihl R, Brinkmeyer J. Differential diagnosis of aging, dementia of the Alzheimer type and depression with EEG-segmentation. Dement Geriatr Cogn Disord. 1999 Mar-Apr;10(2):64-9. PMID: 10026377
Ihl R, Grass-Kapanke B, Jänner M, Weyer G. Neuropsychometric tests in cross sectional and longitudinal studies - a regression analysis of ADAS - cog, SKT and MMSE. Pharmacopsychiatry. 1999 Nov;32(6):248-54. PMID: 10599935
What is the greatest void to date in our knowledge of Alzheimer's Disease?
To insist on the amyloid hypothesis as well as on the MMSE.
What are the top three papers (not yours) you have read recently?

If resources were not limited, what research projects would you pursue?
Optimize the methodology of non-pharamceutical treatment studies.
What is your leading hypothesis?
A metabolic defect causes Alzheimers.
What piece of missing evidence would help prove it?
Find the starting point.
What is your fallback position?
Will depend on what is falsified.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad